checkAd

     145  0 Kommentare Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock - Seite 2

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, Longboard’s expectations regarding the completion, timing and size of the proposed offering, Longboard’s expectations with respect to granting the underwriters a 30-day option to purchase additional shares and expected timing for topline data. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “expects,” “may,” “will,” “potential,” “focused on,” “working to,” “designed to,” “plans to” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Longboard’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Longboard’s ongoing and planned clinical trials and its business in general, macroeconomic events stemming from evolving geopolitical developments such as the conflicts in Ukraine and the Middle East and the other risks described in Longboard’s filings with the SEC, including under the heading “Risk Factors” contained therein, as well as the risks identified in the registration statements and the preliminary prospectus supplement relating to the proposed public offering. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Longboard undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

    Lesen Sie auch


    The Longboard Pharmaceuticals Stock at the time of publication of the news with a raise of +283,58 % to 23,13USD on Nasdaq stock exchange (02. Januar 2024, 21:46 Uhr).
    Seite 2 von 2




    Business Wire (engl.)
    0 Follower
    Autor folgen

    Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock - Seite 2 Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has commenced an underwritten public offering, …